Vertex Pharmaceuticals Incorporated (VRTX) is a Biotechnology company in the Healthcare sector, currently trading at $444.28. It has a SharesGrow Score of 84/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of VRTX = $645.55 (+45.3% from the current price, the stock appears undervalued). Analyst consensus target is VRTX = $550 (+23.7% upside).
Valuation: VRTX trades at a trailing Price-to-Earnings (P/E) of 28.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.89.
Financials: revenue is $12.1B, +10.6%/yr average growth. Net income is $4.0B, growing at +244.1%/yr. Net profit margin is 32.7% (strong). Gross margin is 85% (-2.9 pp trend).
Balance sheet: total debt is $3.9B against $18.7B equity (Debt-to-Equity (D/E) ratio 0.21, conservative). Current ratio is 2.9 (strong liquidity). Debt-to-assets is 14.9%. Total assets: $26.1B.
Analyst outlook: 47 / 55 analysts rate VRTX as buy (85%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 52/100 (Partial), Growth 90/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 81/100 (Pass), Future 88/100 (Pass), Income 100/100 (Pass).
